Solid IO

A welcome clarification for functional precision medicine! 🔬 American Society of Clinical Oncology (ASCO) has clarified the status of Functional Precision Medicine (FPM) in oncology. FPM combines genomic and molecular information with functional testing of how living, patient-derived tumor material responds to treatments outside the body. The new Clinical Notice distinguishes modern FPM from early chemosensitivity assays covered by archived guidance from 2004 and 2011. ASCO explicitly supports the advancement of the field, while noting that the evidence base for clinical use is still maturing. For Solid IO, this matters.  Our tumor-on-chip platform uses intact patient-derived tumor tissue to generate functional data while preserving the tumor immune microenvironment. This allows us to study how treatments affect tumor and immune cells together. Clearer definitions and stronger evidence standards allow modern functional approaches to be evaluated based on current science and real clinical evidence. Link to the ASCO Clinical Notice here 👇 https://lnkd.in/g3sRKpbU #FunctionalPrecisionMedicine #PrecisionOncology 

Why do some lung cancer patients benefit from immunotherapy while others don't? Despite major advances in cancer treatment, many patients still don't achieve durable responses to current immunotherapies. Understanding the biology behind treatment resistance remains one of the biggest challenges in oncology. This week at the 50th FEBS Congress in Maastricht, our CSO Heidi Haikala shared new findings on how the spatial organization of the tumor immune microenvironment, and the role of cancer-associated fibroblasts (CAFs), may physically suppress anti-tumor immune responses. In her presentation, "Outsmarting Lung Cancer: Studying Immunotherapy Resistance Using Fully Human Model Systems", she demonstrated how advanced human-relevant models can help uncover the mechanisms driving immunotherapy resistance and provide insights that could support the development of more effective treatment strategies. Thank you to the FEBS organizers for bringing together researchers dedicated to advancing our understanding of cancer biology and improving patient outcomes. #FEBSCongress2026 

📣 We are excited to welcome LSI Zeta and Leo Capital to support our next phase of growth in personalized immuno-oncology. Building a globally relevant life science company takes much more than capital. It requires partners who understand both the scientific and commercial realities of healthcare innovation. At an early stage, we also value investors who are genuinely willing to support the team beyond capital. A big thank you to Kristofer Klerfalk, Ann-Charlotte Beckman and Magnus Klaesson from Life Science Invest, and Olga Balakina and Shwetank Verma from Leo Capital, our existing investors Nordic Science Investments and BSV Ventures, and everyone who has supported us along the way. 🌟 Read more: https://lnkd.in/eMayqsaD

Solid IO has been selected as one of the semifinalists in EIT - European Institute of Innovation and Technology's EIT Health Catapult 10th Edition programme, Europe's leading startup competition for life sciences and healthtech. 🔥 We're proud to be part of this impressive group of innovators building the future of European healthcare. For us, it's validation that the problem we're solving is one the European health ecosystem takes seriously: making sure that there are substantially more immunotherapies reaching the right patients at the right time, and cost efficiently. Looking forward in connecting with the other fellow companies, industry leaders, top investors, and mentors across Europe. Congratulations to all fellow semifinalists: Akasi Pharma | Diamante Società Benefit Srl | FcR Therapeutics | MicThera | NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) | Oniria Therapeutics | OvartiX | Panosome GmbH | POLBIONICA | Provasctec | aiomics | Alithea Bio | BIOS Medical | CLARO Surgical | Debios Diagnostics | FindAir | Flux Robotics 🧲 | heecap | Levels Diagnostics | Loop Dx | RareSum | Metyos | Omniloy | Rebrain. | Sencilia | Strive Health | TimeTeller GmbH | Twente Medical Optics | XO Life EIT Health | bioRN Life Science Cluster | Medical Valley EMN e. V. | Cap Digital  #EITHCatapult #EITHealthCatapult #Catapult10thEdition

For us, nothing beats direct feedback from clinicians closest to patients. Today our CEO Noora Hujala shared our vision to personalize the future of immuno-oncology at bio:cap event in Berlin, followed by feedback from clinicians at Charité, BIH, and AP-HP. Thank you all the clinicians taking part of this important session, and bio:cap, BioLabs, and Berlin Institute of Health for bringing founders, clinicians, investors, and partners under the same roof. Great to be part of the rise of European biotech. 🚀 #biocapEurope #LifeSciences #biocap26 #VentureCapital #MesseBerlin #EuropeanInnovation

EACR 2026 is underway in Budapest, bringing together cancer researchers from around the world to share the latest advances in cancer science. Our CSO, Heidi Haikala, is taking the stage today, presenting her latest research on tumor-immune circuits in lung cancer during a special session hosted by 10x Genomics. Her work highlights the complex interactions between tumors and immune cells, and how transcriptomics is helping us decode what's really happening inside the tumor microenvironment. Exciting science, and great to be part of the conversation at #EACR2026. 🔬 #CancerResearch #TumorMicroenvironment #LungCancer #SingleCell #Immunotherapy 

🏆 Recognition: CSO Heidi Haikala receives the Anders Jahre Prize for Young Scientists. The award from the University of Oslo 🇳🇴 recognizes her work on understanding why cancer therapies stop working, with the goal of preventing treatment resistance and identifying new therapeutic targets. 👉 Read more: https://lnkd.in/dx6W-Rbm

Helsinki is the place to be tomorrow for deep tech innovation and investment. 🔥 Opening the event: Finland's Minister for Foreign Affairs, Elina Valtonen. Meet our CEO Noora and CSO Heidi on life Science stage: 14:00 - Solid IO Pitch 16:30 - The Cure for Cancer – Changing Narratives in Cure Development panel I'll see you soon! 👋

📣 Big news for Solid IO: Peter Loskill has joined us as Scientific Advisor. Dr. Loskill is one of the leading scientific voices in organ-on-chip and predictive medicine: ⭐ Professor and Scientific Director of the Institute of Biomedical Engineering (IBE) at University of Tübingen ⭐ Professor of NMI Natural and Medical Sciences Institute ⭐ Director of the 3R-Center Tübingen ⭐ Co-Founder of the European Organ-on-Chip Society (EUROoCS) Peter's research focuses on advanced microphysiological platforms that replicate human tissue environments with high biological relevance. With over 80 peer-reviewed publications, his work has truly defined the field. “Peter has been one of the people shaping the organ-on-chip field from its early stages. His work combines engineering, biology, physics, and medicine in a way that is directly relevant to what we are building at Solid IO. We are developing patient-derived tumor models that preserve key features of human biology and produce data that can be used to guide treatment decisions. Peter’s experience in building and validating microphysiological systems brings exactly the kind of scientific perspective we need as we move this work toward clinical use.” — Heidi Haikala, CSO, Solid IO A warm welcome Peter! 👉 Read why Peter couldn't say no to Solid IO: https://lnkd.in/dRsbuV48

Positive buzz filled Helsinki today as the Bridge Summit ’26 brought together innovators, startups, and industry leaders to discuss the future of science-driven innovation and collaboration. Solid IO was proud to be part of the conversation. Our CEO Noora Hujala joined the panel on corporate and university spinout collaboration together with Arto Pakkalin from Bayer, Kaisa Helminen from Aiforia Technologies and Harri Kallioinen from Valio, sharing perspectives on how startups and large organisations can build faster, smarter, and more impactful partnerships beyond internal R&D. ✨ We were also excited to see our CSO Heidi Haikala speaking about timor models and the future of more predictive translational research. ✨ Thank you Helsinki Innovation Services Ltd for bringing together all the relevant stakeholders! 🙏